Search

Your search keyword '"Bologna, Serge"' showing total 6 results
Start Over Author "Bologna, Serge" Database Complementary Index
6 results on '"Bologna, Serge"'

1. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy.

Author

Duléry, Rémy, Lamure, Sylvain, Delord, Marc, Di Blasi, Roberta, Chauchet, Adrien, Hueso, Thomas, Rossi, Cédric, Drenou, Bernard, Deau Fischer, Bénédicte, Soussain, Carole, Feugier, Pierre, Noël, Nicolas, Choquet, Sylvain, Bologna, Serge, Joly, Bertrand, Philippe, Laure, Kohn, Milena, Malak, Sandra, Fouquet, Guillemette, and Daguindau, Etienne

Published
2021
Full Text
View/download PDF

2. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Author

Maurer, Matthew J., Jais, Jean-Philippe, Ghesquières, Hervé, Witzig, Thomas E., Hong, Fangxin, Haioun, Corinne, Thompson, Carrie A., Thieblemont, Catherine, Micallef, Ivana N., Porrata, Luis F., Ribrag, Vincent, Nowakowski, Gregorz S., Casasnovas, Olivier, Bologna, Serge, Morschhauser, Franck, Morrison, Vicki A., Peterson, Bruce A., Macon, William R., Copie-Bergman, Christiane, and Feldman, Andrew L.

Published
2016
Full Text
View/download PDF

3. Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.

Author

Lefrère, François, Bastit‐Barrau, Dominique, Hequet, Olivier, Bourin, Philippe, Mathieu‐Nafissi, Suzanne, Bohbot, Alain, Tilly, Hervé, Salles, Gilles, Fermé, Christophe, Lapierre, Valérie, Fornecker, Luc, Micléa, Jean‐Michel, Isebaert, Loic, Bologna, Serge, Fitoussi, Olivier, Mounier, Nicolas, and Haioun, Corinne

Subjects
B cell lymphoma, RITUXIMAB, CD34 antigen, MONOCLONAL antibodies, STEM cell transplantation, COHORT analysis, DOXORUBICIN, IMMUNOCHEMISTRY, PATIENTS
Abstract

BACKGROUND: The ACVBP regimen is an efficient induction regimen for poor-risk patients with diffuse large B-cell lymphoma (DLBCL) before consolidative autologous stem cell transplantation. Adjunction of the monoclonal anti-CD20 antibody rituximab (R-ACVBP) was recently found to be superior to ACVBP alone. This study assessed the impact of rituximab on stem cell mobilization in two similar consecutive groups of patients treated with ACVBP in two prospective, controlled trials. STUDY DESIGN AND METHODS: The first trial (LNH-98B-3) involved 137 patients treated with ACVBP alone. In the second trial (LNH-03-3B), 91 patients received an R-ACVBP regimen. Stem cell mobilization was performed after a course of (R)-ACVBP. RESULTS: The median peak numbers of blood CD34+ cell counts recorded before the first apheresis procedure in the ACVBP and R-ACVBP groups were 69 × 106 and 63 × 106/L, respectively (p = 0.55). The median numbers of CD34+ cells collected were 7.1 × 106 and 6.0 × 106 CD34+ cells/kg for the ACVBP and R-ACVBP groups, respectively (p = 0.13). The median number of apheresis procedures required for gathering the minimum amount of CD34+ cells (2 × 106/kg) was the same in the two groups. CONCLUSION: When compared with ACVBP alone, adjunction of rituximab does not impair stem cell mobilization. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

4. 90Y Ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffer, Bertrand, LeGouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecth, Christian

Published
2011
Full Text
View/download PDF

5. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study.

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffier, Bertrand, Le Gouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecht, Christian

Published
2011
Full Text
View/download PDF

6. Identification of an Acute Basophilic Leukaemia Carrying a Rare e6a2 BCR-ABL Transcript.

Author

Grégoire, Marie-José, Latger-Cannard, Véronique, Staal, Anne, Bologna, Serge, Leotard, Brigitte, Rault, Jean-Philippe, Béry-Dexheimer, Mylène, and Jonveaux, Philippe

Subjects
LEUKEMIA, TRANSCRIPTION factors, LUNG diseases, BLOOD testing, ANEMIA, BLOOD diseases
Abstract

The article presents the case of a 71-year-old male referred to a hospital due to a bilateral pneumopathy. There was no hepatosplenomegaly or cutaneous lesions or symptoms of related hyperhistaminaemia on clinical examination. Peripheral blood analysis resulted to moderate anemia. The case revealed that acute basophilic leukaemia can develop without a history of chronic myelogenous leukaemia.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results